Yatai pharmaceutical (002370.SZ) released its performance forecast for the first half of 2024, with a net profit attributable to shareholders of listed companies of 4.5 million yuan-6.5 million yuan and a year-on-year decrease of 67.12%-77.23%. Net profit after deducting non-recurring gains and losses was a loss of 6.8 million yuan-8.8 million yuan, a decrease of 73.99%-79.90% compared with the same period of last year. Operating income was 220 million yuan-230 million yuan. The basic earnings per share were 0.0074 yuan/share-0.0107 yuan/share.
The net profit attributable to shareholders of listed companies in this period decreased by 67.12%-77.23% compared with the same period of last year, mainly due to the judgment results of the Wuhan Rural Commercial Bank case and investor litigation cases, which led to the reversal of the previously accrued estimate liability of 51.7887 million yuan in the first half of 2023. On June 28, 2024, Bank of China Keqiao Branch, the company's account-opening bank, received the remaining property distribution payment of CAD 2,766,105.25 (approximately RMB 14.4595 million) allocated to YATAI&B&B Biotech Ltd., a joint venture company, for distribution to its shareholder Yatai Pharmaceutical. This led to the corresponding increase in the company's total profit (non-recurring gains and losses) in the first half of 2024.
Excluding the impact of the above non-recurring gains and losses, the company's net profit after deducting non-recurring gains and losses in this period decreased by 73.99%-79.90% compared with the same period of last year, mainly due to the provision of convertible bond interest and the decrease in sales expenses in this period.
